Bangkok Genomics Innovation Pcl
Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand; preimplantation chromosomal abnormality and thalassemia carrier gene screening; infectious disease group analysis; testing for human papilloma virus; and monkeypox virus, COVID… Read more
Bangkok Genomics Innovation Pcl (BKGI) - Net Assets
Latest net assets as of September 2024: ฿524.89 Million THB
Based on the latest financial reports, Bangkok Genomics Innovation Pcl (BKGI) has net assets worth ฿524.89 Million THB as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (฿591.32 Million) and total liabilities (฿66.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ฿524.89 Million |
| % of Total Assets | 88.77% |
| Annual Growth Rate | 71.57% |
| 5-Year Change | 651.42% |
| 10-Year Change | N/A |
| Growth Volatility | 84.02 |
Bangkok Genomics Innovation Pcl - Net Assets Trend (2018–2023)
This chart illustrates how Bangkok Genomics Innovation Pcl's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bangkok Genomics Innovation Pcl (2018–2023)
The table below shows the annual net assets of Bangkok Genomics Innovation Pcl from 2018 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | ฿235.82 Million | -4.79% |
| 2022-12-31 | ฿247.68 Million | +65.95% |
| 2021-12-31 | ฿149.25 Million | +241.98% |
| 2020-12-31 | ฿43.64 Million | +39.07% |
| 2019-12-31 | ฿31.38 Million | +97.75% |
| 2018-12-31 | ฿15.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bangkok Genomics Innovation Pcl's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2179420400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ฿7.66 Million | 3.25% |
| Common Stock | ฿220.00 Million | 93.29% |
| Other Comprehensive Income | ฿8.15 Million | 3.46% |
| Total Equity | ฿235.82 Million | 100.00% |
Bangkok Genomics Innovation Pcl Competitors by Market Cap
The table below lists competitors of Bangkok Genomics Innovation Pcl ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CASH Financial Services Group Limited
F:CFN0
|
$8.21 Million |
|
FORSEE POWER(PROM.)EO-10
F:4OY
|
$8.21 Million |
|
Yangjisa Co. Ltd
KQ:030960
|
$8.21 Million |
|
SINTX Technologies Inc
NASDAQ:SINT
|
$8.22 Million |
|
Christiani & Nielsen (Thai) Public Company Limited
BK:CNT
|
$8.20 Million |
|
Genetic Signatures Ltd
AU:GSS
|
$8.20 Million |
|
Green World Hotels Co., Ltd.
TWO:8077
|
$8.20 Million |
|
Pion Group AB Series B
ST:PION-B
|
$8.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bangkok Genomics Innovation Pcl's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 247,676,782 to 235,818,516, a change of -11,858,266 (-4.8%).
- Net income of 32,141,734 contributed positively to equity growth.
- Dividend payments of 44,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 1,700,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ฿32.14 Million | +13.63% |
| Dividends Paid | ฿44.00 Million | -18.66% |
| Other Comprehensive Income | ฿1.70 Million | +0.72% |
| Other Changes | ฿-1.70 Million | -0.72% |
| Total Change | ฿- | -4.79% |
Book Value vs Market Value Analysis
This analysis compares Bangkok Genomics Innovation Pcl's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.61x to 3.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ฿0.10 | ฿1.35 | x |
| 2019-12-31 | ฿0.20 | ฿1.35 | x |
| 2020-12-31 | ฿0.27 | ฿1.35 | x |
| 2021-12-31 | ฿0.93 | ฿1.35 | x |
| 2022-12-31 | ฿0.41 | ฿1.35 | x |
| 2023-12-31 | ฿0.39 | ฿1.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bangkok Genomics Innovation Pcl utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.63%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.10%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 1.24x
- Recent ROE (13.63%) is below the historical average (18.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -86.66% | -19.44% | 1.20x | 3.71x | ฿-15.34 Million |
| 2019 | 49.43% | 13.04% | 2.24x | 1.69x | ฿12.37 Million |
| 2020 | 31.62% | 10.32% | 1.37x | 2.24x | ฿9.44 Million |
| 2021 | 70.79% | 27.86% | 2.02x | 1.26x | ฿90.74 Million |
| 2022 | 30.33% | 24.65% | 1.01x | 1.21x | ฿50.35 Million |
| 2023 | 13.63% | 13.10% | 0.84x | 1.24x | ฿8.56 Million |
Industry Comparison
This section compares Bangkok Genomics Innovation Pcl's net assets metrics with peer companies in the Diagnostics & Research industry.
No peer company data available for comparison.